약독화 생백신 시장 : 백신 유형, 개발, 연령대, 투여 방법, 적응증, 최종 용도별 - 세계 예측

Live attenuated vaccines market will witness 10.4% CAGR from 2024 to 2032. The long-term protection provided by live vaccines against diseases has led to their widespread use besides their ability to stimulate a strong immune response, further making them cost-effective for immunization programs in underserved areas. Compared to other types, the doses of these live vaccines to provide immunity are lower, reducing vaccine costs and logistical challenges. The ongoing R&D efforts to expand the repertoire of diseases that can be prevented with live vaccines have led to advances in vaccine delivery technology.

Moreover, live vaccines have the advantage of being rapidly developed and modified to target new variants or emerging pathogens. For instance, in November 2023, Indian Immunologicals (IIL) unveiled Mabella, a vaccine for curing measles and rubella in children in an exclusive collaboration with Polyvac Institute of Vietnam. Furthermore, these vaccines stimulate humoral and cellular responses, making them effective in responding to public health threats and reducing disease transmission. The growing cruciality of vaccines in the fight against emerging infectious diseases will also favor the segment growth.

The industry is segmented into vaccine type, development, age group, mode of administration, indication, end-use and region.

Based on vaccine type, the market size from the bacterial vaccine segment is set to witness 10.6% CAGR up to 2032. With bacterial infections becoming a major health burden worldwide, the need for effective preventive measures is increasing. Live vaccines provide an immune response to bacterial pathogens by suppressing natural immunity while providing strong and long-lasting immunity. Rapid advancements in live vaccine technology have also made it possible to develop vaccines against many bacterial diseases, including tuberculosis, typhoid, and whooping cough.

Live attenuated vaccines market from the oral mode of administration segment is anticipated to observe 10.5% CAGR during 2024-2032. Oral vaccines offer a convenient, needle-free option for patients, especially children and vulnerable populations. They improve vaccination rates and provide protection against respiratory and gastrointestinal infections by boosting mucosal immunity.

Asia Pacific live attenuated industry will showcase impressive growth at 10.7% CAGR from 2024-2032. The increasing burden of infectious diseases like tuberculosis, measles, and Japanese encephalitis is fueling the need for effective preventive measures. Rapid urbanization and population growth are increasing the risk of disease transmission, necessitating vaccination programs to control outbreaks and reduce disease burden. Multiple government initiatives are focusing on expanding immunization protocols, enhancing health infrastructure, and strengthening legal frameworks, adding to the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing prevalence of infectious diseases
    • 3.2.1.2 Expanding vaccination programs
    • 3.2.1.3 Growing advancements in vaccine development
    • 3.2.1.4 Robust government support & funding for vaccine development
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost associated with vaccine development
    • 3.2.2.2 Stringent regulations for the approval
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Vaccine Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Bacterial vaccine
• 5.3 Viral vaccine

Chapter 6 Market Estimates and Forecast, By Development, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Tissue culture
• 6.3 Embryonated eggs
• 6.4 Live animals

Chapter 7 Market Estimates and Forecast, By Mode of Administration, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Injectable
• 7.4 Intranasal

Chapter 8 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Pediatric
• 8.3 Adult

Chapter 9 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Tuberculosis
• 9.3 Measles
• 9.4 Rotavirus
• 9.5 Yellow fever
• 9.6 Oral polio
• 9.7 Influenza
• 9.8 Other indications

Chapter 10 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 Hospitals
  • 10.2.1 Public
  • 10.2.2 Private
• 10.3 Specialty clinics
• 10.4 Other end-users

Chapter 11 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 11.1 Key trends, by region
• 11.2 North America
  • 11.2.1 U.S.
  • 11.2.2 Canada
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 France
  • 11.3.4 Spain
  • 11.3.5 Italy
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 Rest of Asia Pacific
• 11.5 Latin America
  • 11.5.1 Brazil
  • 11.5.2 Mexico
  • 11.5.3 Rest of Latin America
• 11.6 Middle East and Africa
  • 11.6.1 South Africa
  • 11.6.2 Saudi Arabia
  • 11.6.3 Rest of Middle East and Africa

Chapter 12 Company Profiles

• 12.1 Abbott
• 12.2 Bharat Biotech International Limited
• 12.3 Boehringer Ingelheim International GmbH
• 12.4 GlaxoSmithKline, plc.
• 12.5 Haffkine Biopharmaceutical Corporation Limited
• 12.6 HBI
• 12.7 Merck & Co.
• 12.8 Novartis Pharmaceuticals Corporation
• 12.9 Sanofi
• 12.10 Serum Institute of India Ltd.
• 12.11 Valneva SE
• 12.12 Zydus Group